12-month results from the real-life observational treat-to-target and tight control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
In this medfyle
NOR-Gout shows T2T leads to satisfactory serum urate levels.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the RMD Open, EULAR’s official journal, through an official agreement with BMJ.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Rene Westhovens, MD, PhD, Rheumatologist, Emeritus Professor KU Leuven, Belgium.
Original article:
Uhlig T, Karoliussen LF, Sexton J, et al. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open 2021;7:e001628. doi: 10.1136/rmdopen-2021-001628
The authors of the original article had no part in the creation of the summary.
Copyright © 2020 BMJ Publishing Group Limited and Globalport (International) Limited. All rights reserved.
The summaries, expert commentaries and slides included in this Medfyle are co-owned by BMJ and GlobalPort (International) Limited. The original journal article is an exclusive copyright of BMJ Publishing Group Limited.
